Meta Analysis Of CCB Combined With ARB In The Treatment Of Diabetic Nephropathy Complicated With Hypertension

Objective: To evaluated the efficacy and safety of CCB combined with ARB in the treatment of diabetic nephropathy with hypertension.A systematic evaluation of calcium channel blocker combined with vangiotensin Ⅱ receptor blockers in the treatment of ⅡI-IV stage diabetic nephropathy with hypertension efficacy and safety.Method: The computer retrievals were made in the Pub Med database,Embase,Cochrane Libarary,CNKI,Wanfang DATA,VIP etc.(Updated to November 2015),in order to collect randomized controlled trials for CCB agents with ARB agents for the treatment of type 2 diabetes nephropathy combined with hypertension.Set the literature inclusion and exclusion criteria.,and carries on the literature quality evaluation.Rev Man 5.2 software were used for a Meta analysis.Result: A total of 16 randomized controlled trials were included in 871 patients.The Meta analysis result showed that compared with the control group,the combination group showed better effects in reducing the SBP [SMD=-1.11,95%CI(-1.25,-0.96)],DBP [MD=-9.79,95%CI(-10.88,-8.70)],UAER [MD=-17.62,95%CI(-21.54,-13.71)],Scr [MD=-7.05,95%CI(-10.00,-4.11)]、BUN [SMD=-0.39,95%CI(-0.58,-0.21)].The difference of adverse reactions in the two groups was not statistically significant.Conclusion: CCB combined with ARB in the treatment of type 2 diabetic nephropathy combined with hypertension and protect renal function is better than that of ARB alone.